title: Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management.
abstract: The prostate is an androgen-dependent organ. The increase, growth, homeostasis, and function of the prostate largely depend upon the intraprostatic and serum concentrations of androgens. Therefore, androgens are essential for the physiologic growth of prostatic epithelium. Prostate cancer, the second leading cause of death for men, is also androgen dependent, and androgen suppression is the mainstay of treatment for advanced and metastatic disease. In the state of metastatic disease, androgen suppression is a palliative treatment leading to a median progression-free survival of 18-20 months and an overall survival of 24-36 months. Theoretically, the majority of patients will develop hormone-refractory disease provided that they will not die from other causes. Although androgen suppression therapy may be associated with significant and sometimes durable responses, it is not considered a cure, and its potential efficacy is further limited by an array of significant and bothersome adverse effects caused by the suppression of androgens. These effects have potentially significant consequences on a variety of parameters of everyday living and may further decrease health-related quality of life. This review focuses on the aetiology of these adverse effects and provides information on their prevention and management.
authors: Urology Department, General Hospital of Veria, 55133 Thessaloniki, Greece.
authors: Petros
authors: P
authors: Sountoulides
authors: Thomas
authors: T
authors: Rountos
references: Psychoneuroendocrinology. 2004 Sep;29(8):1071-81
references: 15219659
references: Urol Oncol. 2013 Oct;31(7):1098-105
references: 22285008
references: BJU Int. 2013 Apr;111(4):543-8
references: 23351025
references: BJU Int. 2005 Sep;96(4):514-20
references: 16104902
references: Urology. 2001 Aug;58(2 Suppl 1):5-9
references: 11502435
references: Rev Urol. 2005;7 Suppl 5:S37-43
references: 16985883
references: J Urol. 2004 Aug;172(2):529-32
references: 15247721
references: BJU Int. 2006 Jul;98(1):20-7
references: 16566812
references: J Urol. 2003 Jun;169(6):2008-12
references: 12771706
references: J Support Oncol. 2010 May-Jun;8(3):128-32
references: 20552926
references: Urology. 2010 Mar;75(3):642-7
references: 19962733
references: J Clin Oncol. 2005 Nov 10;23(32):8212-8
references: 16278475
references: J Clin Oncol. 2007 Jun 10;25(17):2420-5
references: 17557956
references: Lancet. 2011 Mar 5;377(9768):813-22
references: 21353695
references: J Urol. 2004 Nov;172(5 Pt 1):1865-70
references: 15540740
references: Urol Oncol. 2013 Apr;31(3):352-8
references: 21803612
references: J Clin Oncol. 1999 Mar;17(3):1087-8
references: 10071307
references: J Urol. 2009 May;181(5):1998-2006; discussion 2007-8
references: 19286225
references: Br J Urol. 1997 Feb;79(2):235-46
references: 9052476
references: Cancer. 2012 Apr 1;118(7):1940-5
references: 22009684
references: Lancet. 2012 Jan 7;379(9810):39-46
references: 22093187
references: Lancet Oncol. 2010 Feb;11(2):147-54
references: 19963436
references: J Urol. 2002 Sep;168(3):1005-7
references: 12187209
references: Crit Rev Oncol Hematol. 2013 Sep;87(3):224-38
references: 23484454
references: Oncologist. 2012;17(2):288-90
references: 22267850
references: BJU Int. 2008 Jul;102(1):39-43
references: 18294309
references: Prog Urol. 2009 Jan;19(1):47-53
references: 19135642
references: Prostate. 2004 Dec 1;61(4):332-53
references: 15389811
references: Hematol Oncol Clin North Am. 2001 Jun;15(3):559-71
references: 11525297
references: Oncologist. 2011;16(11):1658-64
references: 22042786
references: Urology. 2008 Apr;71(4):735-9
references: 18279933
references: N Engl J Med. 1994 Aug 11;331(6):347-52
references: 8028614
references: J Endocrinol Invest. 2009 Sep;32(8):704-16
references: 19494706
references: Maturitas. 2010 Jan;65(1):15-22
references: 19962840
references: Clin J Oncol Nurs. 2011 Apr;15(2):149-57
references: 21444282
references: Asian J Androl. 2012 Mar;14(2):226-31
references: 22231296
references: Eur Urol. 2012 Jan;61(1):11-25
references: 21871711
references: Cancer. 2000 Feb 15;88(4):825-34
references: 10679652
references: CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41
references: 22700443
references: Endocr Regul. 2011 Oct;45(4):199-204
references: 22073949
references: J Urol. 1999 Jul;162(1):98-102
references: 10379749
references: JAMA. 2012 Jan 18;307(3):255-6
references: 22253389
references: Mayo Clin Proc. 2002 Nov;77(11):1207-18
references: 12440557
references: Geriatrics. 2007 Nov;62(11):18-21
references: 17999566
references: Rev Urol. 2007;9 Suppl 1:S3-8
references: 17387371
references: JAMA. 2002 Dec 4;288(21):2709-16
references: 12460094
references: JAMA. 2005 Jul 13;294(2):238-44
references: 16014598
references: J Urol. 2004 Dec;172(6 Pt 1):2208-12
references: 15538233
references: Urol Oncol. 2003 Sep-Oct;21(5):380-3
references: 14670549
references: Can J Urol. 2005 Feb;12(1):2547-52
references: 15777493
references: Cancer. 2004 Aug 1;101(3):541-9
references: 15274067
references: N Engl J Med. 2010 Nov 4;363(19):1822-32
references: 21047226
references: J Support Oncol. 2003 Nov-Dec;1(4):263-6, 269-70, 272-3; discussion 267-8, 271-2
references: 15334868
references: Curr Urol Rep. 2004 Jun;5(3):188-96
references: 15161567
references: J Clin Oncol. 2010 Jan 10;28(2):340-7
references: 19949016
references: N Engl J Med. 2005 Jan 13;352(2):154-64
references: 15647578
references: J Urol. 2002 May;167(5):1952-6
references: 11956415
references: Oncologist. 2003;8(3):259-69
references: 12773748
references: J Urol. 2001 Nov;166(5):1724-8
references: 11586210
references: J Clin Oncol. 2011 Sep 20;29(27):3705-14
references: 21860001
references: J Clin Oncol. 2006 Sep 20;24(27):4448-56
references: 16983113
references: Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1299-305
references: 15817331
references: Asian J Androl. 2012 Mar;14(2):193-7
references: 22286861
references: J Urol. 2011 Oct;186(4):1291-7
references: 21849187